XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Cash flows from operating activities:      
Net loss $ (29,288,867) $ (32,350,828)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 930,907 897,709  
Amortization of intangible assets 266,563 404,062  
Change in value of common stock warrants 0 127,841  
Stock-based compensation 3,432,796 3,575,750  
Non-cash interest expense 656,248 0  
Amortization of premiums on investments 1,908 55,522  
Loss on short-term investments 35,839 253,316  
Loss (gain) on equity investment in affiliated entities 750,103 (2,380,423)  
Tax benefit from other unrealized gains on short-term investments (217,820) 0  
Changes in operating assets and liabilities:      
Accounts receivable 533,097 855,354  
Accounts receivable from affiliated entities (557,154) (1,755,950)  
Prepaid expenses and other current assets 19,789 598,891  
Prepaid expenses and other current assets from affiliated entities (320,741) 171,026  
Other assets (311,272) 190,726  
Accounts payable and accrued expenses (6,999,110) (6,363,762)  
Accrued clinical trial expenses 1,487,479 (183,011)  
Accounts payable and accrued expenses due to affiliated entities 337,818 371,798  
Deferred revenue (121,873) 22,900,404  
Deferred revenue from affiliated entities (31,250) (117,943)  
Operating lease right-of-use assets and liabilities, net (136,388) (87,007)  
Deferred grant funding (2,886,843) 0  
Deferred grant funding from affiliated entities (12,500) 0  
Other liabilities (23,076) 261,325  
Net cash used in operating activities (32,454,347) (12,575,200)  
Cash flows from investing activities:      
Purchases of investments (65,198,491) (9,568,082)  
Maturities of investments 16,520,095 37,525,434  
Purchases of capital assets (658,731) (1,153,465)  
Net cash (used in) provided by investing activities (49,337,127) 26,803,887  
Cash flows from financing activities:      
Proceeds from issuance of convertible senior notes 75,658,953 0  
Proceeds from issuance of common stock, net of issuance costs 907,330 0  
Taxes paid related to net share settlement of equity awards, net of proceeds from stock option exercises (719,397) (506,403)  
Acquisition of non-controlling interest 3,030,107 0  
Net cash provided by (used in) financing activities 78,876,993 (506,403)  
Increase (decrease) in cash and cash equivalents (2,914,481) 13,722,284  
Cash and cash equivalents, beginning of period 23,693,633 23,786,579 $ 23,786,579
Cash and cash equivalents, end of period 20,779,152 37,508,863 $ 23,693,633
Supplemental disclosure of non-cash activities      
Amounts accrued for purchases of property and equipment $ 68,806 $ 164,288